Theravance Biopharma to Report Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025

2/12/25 6:00:00 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $TBPH alert in real time by email

DUBLIN, Ireland, Feb. 12, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ:TBPH) will report its fourth quarter and full year 2024 financial results and provide a business update after market close on Wednesday, February 26, 2025. An accompanying conference call and simultaneous webcast will be hosted at 5:00 pm EST (2:00 pm PST/10:00 pm GMT) that day.

Conference Call Information

To participate in the live call by telephone, please pre-register here. Those interested in listening to the conference call live via the internet may do so by visiting Theravance Biopharma's website at www.theravance.com, under the Investors section, Events and Presentations.

A replay of the webcast will be available on Theravance Biopharma's website for 30 days through March 28, 2025.

About Theravance Biopharma

Theravance Biopharma, Inc.'s focus is to deliver Medicines that Make a Difference^® in people's lives. In pursuit of its purpose, Theravance Biopharma leverages decades of expertise, which has led to the development of FDA-approved YUPELRI^® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Ampreloxetine, its late-stage investigational once-daily norepinephrine reuptake inhibitor in development for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA), has the potential to be a first in class therapy effective in treating a constellation of cardinal symptoms in MSA patients. The Company is committed to creating/driving shareholder value.

For more information, please visit www.theravance.com.

THERAVANCE BIOPHARMA^®, THERAVANCE^® and the Cross/Star logo are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries).

YUPELRI^® is a registered trademark of Mylan Specialty L.P., a Viatris company. Trademarks, trade names or service marks of other companies appearing in this press release are the property of their respective owners.

Contact:

[email protected]

650-808-4045

View original content to download multimedia:https://www.prnewswire.com/news-releases/theravance-biopharma-to-report-fourth-quarter-and-full-year-2024-financial-results-on-february-26-2025-302374229.html

SOURCE Theravance Biopharma, Inc.

Get the next $TBPH alert in real time by email

Recent Analyst Ratings for

$TBPH

Date	Price Target	Rating	Analyst
8/6/2024	$15.00 → $10.00	Outperform → Market Perform	Leerink Partners
4/12/2024	$21.00	Buy	BTIG Research
1/8/2024		Outperform → In-line	Evercore ISI
5/23/2022	$12.00	Outperform	SVB Leerink
3/2/2022	$10.00 → $11.00	Underweight	Morgan Stanley
2/24/2022	$8.00 → $12.00	Buy	HC Wainwright & Co.
11/5/2021	$7.00 → $12.00	Underweight → Neutral	JP Morgan
9/16/2021	$14.00 → $10.00	Underweight	Morgan Stanley

More analyst ratings

Theravance Biopharma to Report Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025

Chat with this insight

Recent Analyst Ratings for
$TBPH

$TBPH
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

CHIEF EXECUTIVE OFFICER Winningham Rick E gifted 9,600 units of Ordinary Shares and received a gift of 9,600 units of Ordinary Shares, decreasing direct ownership by 0.54% to 1,753,180 units (SEC Form 4)

SVP, COMM & MEDICAL AFFAIRS Farnum Rhonda sold $264,000 worth of Ordinary Shares (24,000 units at $11.00), decreasing direct ownership by 7% to 336,918 units (SEC Form 4)

CHIEF EXECUTIVE OFFICER Winningham Rick E covered exercise/tax liability with 15,364 units of Ordinary Shares, decreasing direct ownership by 0.86% to 1,762,780 units (SEC Form 4)

$TBPH
Press Releases

Fastest customizable press release news feed in the world

Theravance Biopharma, Inc. Sells Remaining Royalty Interest in Trelegy Ellipta to GSK for $225 Million

Theravance Biopharma to Participate in an Upcoming Investor Conference

Theravance Biopharma Announces Ampreloxetine Presentations at the International MSA Congress

$TBPH
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Large owner Samaha Eli bought $7,798,440 worth of COM (999,800 units at $7.80) (SEC Form 4)

Samaha Eli bought $13,117,335 worth of COM (1,499,124 units at $8.75) (SEC Form 4)

$TBPH
SEC Filings

Theravance Biopharma Inc. filed SEC Form 8-K: Other Events

Theravance Biopharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Regulation FD Disclosure, Financial Statements and Exhibits

Theravance Biopharma Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

$TBPH
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Theravance Biopharma downgraded by Leerink Partners with a new price target

BTIG Research initiated coverage on Theravance Biopharma with a new price target

Theravance Biopharma downgraded by Evercore ISI

Theravance Biopharma to Report Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025

Chat with this insight

Recent Analyst Ratings for $TBPH

$TBPH Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

CHIEF EXECUTIVE OFFICER Winningham Rick E gifted 9,600 units of Ordinary Shares and received a gift of 9,600 units of Ordinary Shares, decreasing direct ownership by 0.54% to 1,753,180 units (SEC Form 4)

SVP, COMM & MEDICAL AFFAIRS Farnum Rhonda sold $264,000 worth of Ordinary Shares (24,000 units at $11.00), decreasing direct ownership by 7% to 336,918 units (SEC Form 4)

CHIEF EXECUTIVE OFFICER Winningham Rick E covered exercise/tax liability with 15,364 units of Ordinary Shares, decreasing direct ownership by 0.86% to 1,762,780 units (SEC Form 4)

$TBPH Press Releases

Fastest customizable press release news feed in the world

Theravance Biopharma, Inc. Sells Remaining Royalty Interest in Trelegy Ellipta to GSK for $225 Million

Theravance Biopharma to Participate in an Upcoming Investor Conference

Theravance Biopharma Announces Ampreloxetine Presentations at the International MSA Congress

$TBPH Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Large owner Samaha Eli bought $7,798,440 worth of COM (999,800 units at $7.80) (SEC Form 4)

Samaha Eli bought $13,117,335 worth of COM (1,499,124 units at $8.75) (SEC Form 4)

$TBPH SEC Filings

Theravance Biopharma Inc. filed SEC Form 8-K: Other Events

Theravance Biopharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Regulation FD Disclosure, Financial Statements and Exhibits

Theravance Biopharma Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

$TBPH Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Theravance Biopharma downgraded by Leerink Partners with a new price target

BTIG Research initiated coverage on Theravance Biopharma with a new price target

Theravance Biopharma downgraded by Evercore ISI

Recent Analyst Ratings for
$TBPH

$TBPH
Insider Trading

$TBPH
Press Releases

$TBPH
Insider Purchases

$TBPH
SEC Filings

$TBPH
Analyst Ratings